Glenmark Pharma concludes study on COVID drug Favipiravir

15 Sep 2021 Evaluate

Glenmark Pharmaceuticals has successfully completed its post-marketing surveillance study on Favipiravir in India. The study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients. Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhea, vomiting etc were found to be mild in nature. The time for fever resolution was 4 days, while the time for the clinical cure was 7 days.

The study was conducted at thirteen sites - both government and private institutions - across Mumbai, Bangalore, Hyderabad, Nashik, Nagpur, and Trivandrum. It was conducted in patients in line with the approved indication of the drug.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1178.00 17.25 (1.49%)
03-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1453.25
Dr. Reddys Lab 5792.95
Cipla 1459.85
Zydus Lifesciences 1032.25
Lupin 1583.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.